2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2247

REAL-Life Cost of UK Healthcare Resource for Patients with Rheumatoid Arthritis, Comparing High and Low/Remission Disease States
Abstract Number: 2248

The “Financial Toxicity” of Therapy in Patients with Rheumatoid Arthritis
Abstract Number: 2249

Comparison of Discontinuation Rates Among Patients with RA Initiating Biologics
Abstract Number: 2250

A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Abstract Number: 2251

Secukinumab Vs Adalimumab for the Treatment of Ankylosing Spondylitis: A Cost per Responder Analysis at 52 Weeks from the US Perspective
Abstract Number: 2252

Estimated Cost of SLE Hospitalizations
Abstract Number: 2253

Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France
Abstract Number: 2254

Patient Adherence with Biologic Therapy in Rheumatoid Arthritis: A Real-World Review of Compliance
Abstract Number: 2255

Characterization of Low-Density Granulocytes in Autoinflammatory Disorders
Abstract Number: 2256

Histopathologic Features and Tissue Interferon-Response Gene Scoring of Lesional Skin Samples for Diagnosis in Autoinflammatory Disorders
Abstract Number: 2257

Regulation of Mitochondrial Proton Gradient Is Critical for NLRP3 Inflammasome Activation
Abstract Number: 2258

Role of NLRP12 on Disease Severity in Autoimmune Arthritis
Abstract Number: 2259

Suppression of Monosodium Urate Crystal-Induced Cytokine Production Via Inhibition of Histone Deacetylases 1/2
Abstract Number: 2260

Anti-Inflammatory Role of Lubricin/Proteoglycan 4 (PRG4) in Monosodium Urate (MSU)-Crystal Induced Arthritis.
Abstract Number: 2261

Methotrexate Inhibits Intracellular Redox Signaling Induced By the Reactive Oxygen Species; Malondialdehyde and Acetaldehyde

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].